LaserSight Gets FDA Approval for 200-Hz Performance
WINTER PARK, Fla., Nov. 2 -- LaserSight Inc. said its PMA supplement to increase the repetition rate of its LaserScan LSX microspot scanning system to 200 Hz for the LASIK treatment of myopia and myopic astigmatism was approved by the FDA. The PMA supplement was submitted to the FDA on Oct. 5 with a request for review on a 30-day real-time basis.
This approval is necessary for the launch of the LaserScan LSX, which is the only laser system approved in the US that combines a 200-Hz repetition rate, a microspot and the high resolution of optimized low-laser fluence.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024